Entera Bio (NASDAQ:ENTX) Stock Price Down 2.4% – Time to Sell?

Posted by Geri Gentry on Jun 5th, 2026

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report)’s share price dropped 2.4% during trading on Wednesday . The company traded as low as $1.1950 and last traded at $1.22. Approximately 44,154 shares were traded during trading, a decline of 53% from the average daily volume of 93,334 shares. The stock had previously closed at $1.25.

Analyst Ratings Changes

Several research firms have weighed in on ENTX. HC Wainwright lowered their target price on shares of Entera Bio from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Entera Bio presently has a consensus rating of “Hold” and an average target price of $9.00.

Get Our Latest Report on ENTX

Entera Bio Stock Down 3.3%

The company’s fifty day moving average price is $1.21 and its two-hundred day moving average price is $1.52. The company has a market cap of $58.09 million, a price-to-earnings ratio of -4.37 and a beta of 1.56.

Entera Bio (NASDAQ:ENTX – Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. On average, equities research analysts predict that Entera Bio Ltd. will post -0.34 earnings per share for the current fiscal year.

Insider Activity at Entera Bio

In other news, Director Geno J. Germano acquired 20,000 shares of Entera Bio stock in a transaction dated Monday, March 9th. The stock was bought at an average cost of $1.30 per share, with a total value of $26,000.00. Following the completion of the transaction, the director directly owned 40,000 shares of the company’s stock, valued at approximately $52,000. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.38% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Entera Bio

Several institutional investors have recently bought and sold shares of the company. Superstring Capital Management LP bought a new position in Entera Bio in the fourth quarter valued at $33,000. Citadel Advisors LLC boosted its stake in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after buying an additional 28,322 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Entera Bio by 142.6% in the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after acquiring an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after acquiring an additional 19,601 shares in the last quarter. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

(Get Free Report)

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.